ImmunityBio (IBRX) Investor presentation summary

Platform and pipeline overview

• Immunotherapy platforms integrate cytokines, vaccines, and cellular therapies targeting NK, CD4+, CD8+ killer T cells, and memory T cells for durable responses across multiple tumor types.

• ANKTIVA is central to the pipeline, with applications in NMIBC, NSCLC, and pancreatic cancer, and is combined with BCG, checkpoint inhibitors, and CAR-NK therapies.

• Multiple global regulatory approvals achieved: US FDA (2024), UK MHRA (2025), EU EMA (2026), and Saudi FDA (2026).

Clinical and regulatory progress

• ANKTIVA demonstrated 53+ months median duration of response in BCG-unresponsive NMIBC, outperforming other therapies.

• 84% of responders retained their bladders, and 71% achieved complete response; 99% disease-specific survival at 36 months.

• Pivotal phase 3 trial in BCG-naïve NMIBC completed enrollment (Feb 2026), with interim analysis showing 84% CR for ANKTIVA+BCG vs. 52% for BCG alone.

• Expanded Access Program for recombinant BCG addresses global shortages, with exclusive supply agreement with Serum Institute of India.

Commercial execution and financials

• ANKTIVA launched in May 2024, with rapid payer adoption and inclusion in NCCN guidelines and J-Code assignment.

• Product revenue grew from $1M in Q2 2024 to $38.3M in Q4 2025, with ~700% CAGR and consistent quarterly growth.

• Unit volume increased from 29 in Q2 2024 to 1,245 in Q4 2025, reflecting ~750% CAGR.

• Cash and marketable securities totaled $242.8M at Q4 2025, supporting operations through multiple catalysts.